China SXT Pharmaceuticals, Inc. (SXTC) stock
SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
$3.00+0.27 (+9.89%)
Close on Nov 13, 2026Market cap $2.87MP/E –Yield –
China SXT Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
China SXT Pharmaceuticals's total debt was $999.57K at Mar 31, 2026. For fiscal 2026 it was $999.57K, up 23.8% from the year before. The highest annual figure on record is $999.57K in fiscal 2026.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $999.57K | +23.8% |
| FY2025 | Mar 31, 2025 | $807.23K | +27.8% |
| FY2024 | Mar 31, 2024 | $631.51K | +115.4% |
| FY2023 | Mar 31, 2023 | $293.18K | +1185.4% |
| FY2022 | Mar 31, 2022 | $22.81K | -47.5% |
| FY2021 | Mar 31, 2021 | $43.41K | -1.1% |
| FY2020 | Mar 31, 2020 | $43.90K | +57.8% |
| FY2019 | Mar 31, 2019 | $27.82K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $999.57K | +58.3% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $1.05M | +167.8% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $807.23K | +175.3% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $826.61K | +3524.2% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $631.51K | +2526.7% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $393.58K | +806.6% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $293.18K | +540.7% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $22.81K | -48.0% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $24.04K | -44.7% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $43.41K | +56.1% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $45.76K | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $43.90K | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $43.49K | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $27.82K | – |
See a number that looks wrong?